MacroGenics, Inc. (MGNX) vs Anbio Biotechnology Class A Ordinary Shares (NNNN)
A side-by-side comparison of MacroGenics, Inc. and Anbio Biotechnology Class A Ordinary Shares across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
MGNX
MacroGenics, Inc.
$3.67HealthcareDelayed quote: Oct 6, 2026, 3:50 PM EDT
NNNN
Anbio Biotechnology Class A Ordinary Shares
$4.82HealthcareDelayed quote: Oct 6, 2026, 3:50 PM EDT
Total return — MGNX vs NNNN
growth of $100 · dividends reinvested · last 2yMGNX +29.6% (+13.8%/yr)NNNN -16.3% (-8.5%/yr)MGNX compounded faster over this window
MGNX NNNN
MGNX vs NNNN: by the numbers
- •MGNX is the larger company ($233M vs $212M market cap).
- •NNNN is profitable (74.06% net margin) while MGNX runs a net loss (-8.70%).
Metrics side by side
Valuation
| Metric | MGNX | NNNN |
|---|---|---|
| P/S ratio | 1.39 | N/A |
| P/B ratio | 5.44 | 7.02 |
Profitability
| Metric | MGNX | NNNN |
|---|---|---|
| Gross margin | 71.12% | 87.24% |
| Operating margin | -48.72% | 66.70% |
| Net margin | -8.70% | 74.06% |
| ROE | -34.04% | 21.24% |
| ROIC | -16.87% | 19.13% |
Growth (annualized)
| Metric | MGNX | NNNN |
|---|---|---|
| Revenue CAGR (5Y) | 7.33% | N/A |
| Total return CAGR (5Y) | -28.42% | N/A |
Frequently asked
- Is MGNX or NNNN more profitable?
- NNNN runs the higher net margin — MGNX at -8.70% versus NNNN at 74.06%.
Go deeper
Dig into the metrics
MacroGenics ROEAnbio Biotechnology Class A Ordinary Shares ROEMacroGenics operating marginAnbio Biotechnology Class A Ordinary Shares operating marginMacroGenics revenue growthAnbio Biotechnology Class A Ordinary Shares revenue growthMacroGenics free cash flowAnbio Biotechnology Class A Ordinary Shares free cash flow
MacroGenics & Anbio Biotechnology Class A Ordinary Shares appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.